Enablers and barriers affecting medication-taking behaviour in aging men with benign prostatic hyperplasia

References

• Matyus P, Horvath K. Alpha-adrenergic approach in the medical management of benign prostatic hyperplasia. Med Res Rev 1997;17:523–35
   Google Scholar
• Pennefather JN, Lau WA, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000;20:193–206
   PubMedGoogle Scholar
• Roehrborn C. Benign prostatic hyperplasia and lower urinary tract symptom guidelines. Can Urol Assoc J 2012;6:S130–2
   PubMedGoogle Scholar
• Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361:1359–67
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008;20:S11–18
   PubMed Web of Science ®Google Scholar
• Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 2006;7:272–81
   PubMedGoogle Scholar
• Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 1999;162:1301–6
   PubMed Web of Science ®Google Scholar
• Miner MM. Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ? Curr Urol Rep 2009;10:254–60
   Google Scholar
• de la Rosette JJ, Alivizatos G, Madersbacher S, et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001;40:256–63; discussion 264
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547–54
   PubMed Web of Science ®Google Scholar
• Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol 2004;14:13–16
   PubMed Web of Science ®Google Scholar
• Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003;61:354–8
   PubMed Web of Science ®Google Scholar
• Cervenakov I, Fillo J, Mardiak J, et al. Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker – Tamsulosin. Int Urol Nephrol 2002;34:25–9
   PubMedGoogle Scholar
• Chapple CR. Alpha adrenoceptor antagonists in the year 2000: is there anything new? Curr Opin Urol 2001;11:9–16
   PubMedGoogle Scholar
• Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999;54:420–3
   PubMed Web of Science ®Google Scholar
• Leedahl DD, Vo PH, Maxson PM, Lovely JK. Benign prostatic hyperplasia: implications for pharmacologic treatment and perioperative care. J Pharm Pract 2012 [Epub ahead of print]
   Google Scholar
• Lin YH, Jiang YG, Wang JS, Luo Y. Finasteride adherence-associated factors in Chinese benign prostatic hyperplasia patients. Urol Int 2012;88:177–82
   Google Scholar
• Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 2009;181:2214-21;discussion 2221–2
   PubMed Web of Science ®Google Scholar
• Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 2005;8:495–505
   PubMed Web of Science ®Google Scholar
• Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; CD000011
   PubMed Web of Science ®Google Scholar
• Johnson MJ. The Medication Adherence Model: a guide for assessing medication taking. Res Theory Nurs Pract 2002;16:179–92
   PubMedGoogle Scholar
• Pound P, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005;61:133–55
   PubMed Web of Science ®Google Scholar
• Lawton J, Peel E, Parry O, Douglas M. Patients' perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. Diabet Med 2008;25:491–5
   Google Scholar
• Williams A, Manias E, Walker R. Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J Adv Nurs 2008;63:132–43
   PubMed Web of Science ®Google Scholar
• Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002;31:S123–7
   PubMed Web of Science ®Google Scholar
• Barclay TR, Hinkin CH, Castellon SA, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol 2007;26:40–9
   PubMed Web of Science ®Google Scholar
• Burge S, White D, Bajorek E, et al. Correlates of medication knowledge and adherence: findings from the residency research network of South Texas. Fam Med 2005;37:712–18
   Web of Science ®Google Scholar
• Cohen I, Rogers P, Burke V, Beilin LJ. Predictors of medication use, compliance and symptoms of hypotension in a community-based sample of elderly men and women. J Clin Pharm Ther 1998;23:423–32
   PubMed Web of Science ®Google Scholar
• Kalichman SC, Rompa D. Functional health literacy is associated with health status and health-related knowledge in people living with HIV-AIDS. J Acquir Immune Defic Syndr 2000;25:337–44
   PubMed Web of Science ®Google Scholar
• Traylor AH, Schmittdiel JA, Uratsu CS, et al. Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter? J Gen Intern Med 2010;25:1172–7
   PubMed Web of Science ®Google Scholar
• Cooper LA, Roter DL, Johnson RL, et al. Patient-centered communication, ratings of care, and concordance of patient and physician race. Ann Intern Med 2003;139:907–15
   PubMed Web of Science ®Google Scholar
• Gazmararian JA, Kripalani S, Miller MJ, et al. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J Gen Intern Med 2006;21:1215–21
   PubMed Web of Science ®Google Scholar
• Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc (Wash) 2000;40:475–85
   PubMedGoogle Scholar
• Michel MC, Mehlburger L, Schumacher H, et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725–9
   PubMed Web of Science ®Google Scholar
• Speakman MJ. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what is the available evidence for rational management? Eur Urol 2001;39:6–12
   Google Scholar
• Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997;10:697–704
   PubMed Web of Science ®Google Scholar
• Nikolaus T, Kruse W, Bach M, et al. Elderly patients' problems with medication. An in-hospital and follow-up study. Eur J Clin Pharmacol 1996;49:255–9
   PubMed Web of Science ®Google Scholar
• Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q 1984;11:1–47
   PubMedGoogle Scholar
• Manias E, Claydon-Platt K, McColl GJ, et al. Managing complex medication regimens: perspectives of consumers with osteoarthritis and healthcare professionals. Ann Pharmacother 2007;41:764–71
   PubMed Web of Science ®Google Scholar